FREEDOM OF INFORMATION SUMMARY
ORIGINAL ABBREVIATED NEW ANIMAL DRUG APPLICATION

ANADA 200-666

Increxxa™
(tulathromycin injection)

Injectable Solution

Beef cattle, non-lactating dairy cattle, suckling calves, dairy calves, veal calves, and swine

**Beef and Non-Lactating Dairy Cattle**

BRD-Increxxa™ Injectable Solution is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni*, and *Mycoplasma bovis*; and for the control of respiratory disease in cattle at high risk of developing BRD associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni*, and *Mycoplasma bovis*.

IBK-Increxxa™ Injectable Solution is indicated for the treatment of infectious bovine keratoconjunctivitis (IBK) associated with *Moraxella bovis*.

Foot Rot-Increxxa™ Injectable Solution is indicated for the treatment of bovine foot rot (interdigital necrobacillosis) associated with *Fusobacterium necrophorum* and *Porphyromonas levii*.

**Suckling Calves, Dairy Calves, and Veal Calves**

BRD-Increxxa™ Injectable Solution is indicated for the treatment of BRD associated with *M. haemolytica*, *P. multocida*, *H. somni*, and *M. bovis*.

**Swine**

Increxxa™ Injectable Solution is indicated for the treatment of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Bordetella bronchiseptica*, *Haemophilus parasuis*, and *Mycoplasma hyopneumoniae*; and for the control of SRD associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, and *Mycoplasma hyopneumoniae* in groups of pigs where SRD has been diagnosed.

Sponsored by:

Elanco US Inc.
# Table of Contents

I. GENERAL INFORMATION .......................................................................................3
II. BIOEQUIVALENCE ................................................................................................4
III. HUMAN FOOD SAFETY ..........................................................................................5
IV. USER SAFETY ......................................................................................................5
V. AGENCY CONCLUSIONS ..........................................................................................6
I. GENERAL INFORMATION

A. File Number
ANADA 200-666

B. Sponsor
Elanco US Inc.
2500 Innovation Way
Greenfield, IN  46140

Drug Labeler Code: 058198

C. Proprietary Name
Increxxa™

D. Drug Product Established Name
tulathromycin injection

E. Pharmacological Category
Antimicrobial

F. Dosage Form
Injectable Solution

G. Amount of Active Ingredient
100 mg of tulathromycin/mL

H. How Supplied
100-mL, 250-mL, and 500-mL vials

I. Dispensing Status
Prescription (Rx)

J. Dosage Regimen

Cattle
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.

Swine
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.

K. Route of Administration
Subcutaneous injection (cattle) and intramuscular injection (swine)
L. **Species/Class**

Beef cattle, non-lactating dairy cattle, suckling calves, dairy calves, veal calves, and swine

M. **Indications**

**Beef and Non-Lactating Dairy Cattle**

**BRD**-Increxxa™ Injectable Solution is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni*, and *Mycoplasma bovis*; and for the control of respiratory disease in cattle at high risk of developing BRD associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni*, and *Mycoplasma bovis*.

**IBK**-Increxxa™ Injectable Solution is indicated for the treatment of infectious bovine keratoconjunctivitis (IBK) associated with *Moraxella bovis*.

**Foot Rot**-Increxxa™ Injectable Solution is indicated for the treatment of bovine foot rot (interdigital necrobacillosis) associated with *Fusobacterium necrophorum* and *Porphyromonas levii*.

**Suckling Calves, Dairy Calves, and Veal Calves**

**BRD**-Increxxa™ Injectable Solution is indicated for the treatment of BRD associated with *M. haemolytica*, *P. multocida*, *H. somni*, and *M. bovis*.

**Swine**

Increxxa™ Injectable Solution is indicated for the treatment of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Bordetella bronchiseptica*, *Haemophilus parasuis*, and *Mycoplasma hyopneumoniae*; and for the control of SRD associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, and *Mycoplasma hyopneumoniae* in groups of pigs where SRD has been diagnosed.

N. **Reference Listed New Animal Drug (RLNAD)**

Draxxin®; tulathromycin injection; NADA 141-244; Zoetis Inc.

II. **BIOEQUIVALENCE**

The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Generic Animal Drug and Patent Term Restoration Act (GADPTRA) of 1988, allows for an abbreviated new animal drug application (ANADA) to be submitted for a generic version of an approved new animal drug (RLNAD). The ANADA sponsor is required to show that the generic product is bioequivalent to the RLNAD, which has been shown to be safe and effective. Effectiveness, target animal safety and human food safety data (other than tissue residue data) are not required for approval of an ANADA. If bioequivalence is demonstrated through a clinical endpoint study in a food-producing animal, then a tissue residue study to establish the withdrawal period for the generic product is also required. For certain dosage forms, the agency will grant a waiver from the requirement to perform *in vivo* bioequivalence studies (biowaiver) (55 FR 24645, June 18, 1990; Fifth GADPTRA Policy Letter; Bioequivalence Guideline, October 9, 2002).

Based on the formulation characteristics of the generic product, Elanco US Inc., was granted a biowaiver for the generic product Increxxa™ (tulathromycin injection) Injectable Solution. The generic drug product is an injectable solution, contains the
same active ingredient in the same concentration and dosage form as the RLNAD, and contains no inactive ingredients that may significantly affect the bioavailability of the active ingredient. The RLNAD is Draxxin® (tulathromycin injection) Injectable Solution, sponsored by Zoetis Inc., under NADA 141-244, and was approved for use in beef cattle, non-lactating dairy cattle, and swine on May 24, 2005.

III. HUMAN FOOD SAFETY

The tolerances for residues and withdrawal periods established for the RLNAD apply to the generic product. The following are assigned to this product for beef cattle, non-lactating dairy cattle, suckling calves, dairy calves, veal calves, and swine:

A. Acceptable Daily Intake and Tolerances for Residues

The acceptable daily intake (ADI) for total residues of tulathromycin is 15 micrograms per kilogram of body weight per day (21 CFR §556.745). The tolerances established for the RLNAD apply to the generic product. A tolerance of 5.5 parts per million (ppm) is established for CP-60,300 (the marker residue) in cattle liver (the target tissue), and a tolerance of 15 ppm is established for CP-60,300 (the marker residue) in swine kidney (the target tissue), under 21 CFR §556.745.

B. Withdrawal Periods

Because a biowaiver was granted, the withdrawal periods are those previously assigned to the RLNAD product. A withdrawal period of 18 days has been established for tulathromycin in beef cattle, non-lactating dairy cattle, suckling calves, dairy calves, and veal calves treated with tulathromycin injection (100 mg/mL) as a single subcutaneous injection in the neck at a dose of 2.5 mg per kg of body weight. A withdrawal period of five days has been established for tulathromycin in swine treated with tulathromycin injection (100 mg/mL) as a single intramuscular injection in the neck at a dose of 2.5 mg per kg of body weight.

C. Analytical Method for Residues

The validated analytical method for analysis of residues of tulathromycin is on file at the Center for Veterinary Medicine, 7500 Standish Place, Rockville, MD 20855. To obtain a copy of the analytical method, please submit a Freedom of Information request to: https://www.accessdata.fda.gov/scripts/foi/FOIRequest/requestinfo.cfm.

IV. USER SAFETY

The product labeling contains the following information regarding safety to humans handling, administering, or exposed to Increxxa™:

FOR USE IN ANIMALS ONLY.
NOT FOR HUMAN USE.
KEEP OUT OF REACH OF CHILDREN.
V. AGENCY CONCLUSIONS

The data submitted in support of this ANADA satisfy the requirements of section 512(c)(2) of the FD&C Act. The data demonstrate that Increxxa™, when used according to the label, is safe and effective for the indications listed in Section I.M. above.

Additionally, data demonstrate that residues in food products derived from beef cattle, non-lactating dairy cattle, suckling calves, dairy calves, veal calves, and swine treated with Increxxa™ will not represent a public health concern when the product is used according to the label.